CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 60 enrolled
Drug / intervention
nicardipinedrug
Likely dose
nicardipine 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00415610
NCT00415610Phase 1Completed
CompareCT.gov

Antihypertensive Treatment in Acute Cerebral Hemorrhage (ATACH)

University of Minnesota·interventional·Posted Dec 25, 2006·Updated Nov 21, 2017

In Brief

A Phase 1 clinical trial evaluating nicardipine for Intracerebral Hemorrhage and 2 related conditions. Completed, enrolled 60 participants across 12 sites.

Detailed Summary

The purpose of this trial is to evaluate the safety and effectiveness of lowering blood pressure using nicardipine in persons with acute hypertension associated with intracerebral hemorrhage.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracerebral Hemorrhage, Hypertension, Stroke
CountriesUnited States
CollaboratorsNational Institute of Neurological Disorders and Stroke (NINDS)

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 25, 2006
Enrollment StartJul 1, 2005
Primary CompletionSep 1, 2007
Study CompletionMar 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.5 years ago

Interventions

nicardipinedrug

Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours. * Started at 5mg/h * Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued.